MSB 2.51% 97.0¢ mesoblast limited

COVID-19 ARDS and ARDS Share Price Scenarios, page-407

  1. 37 Posts.
    lightbulb Created with Sketch. 1
    I know this has been discussed a lot, but it seems the University of Oxford is making huge progress, with governments around the world (including Australia) doing deals in anticipation it's going to go smoothly in both efficacy and safety. It seems to me that any analysis on remestemcel-l to treat COVID19 should be treated with some caution as there is a chance we will have hundreds of millions/billions of doses of an effective vaccine by the end of the year.

    Does anyone have a different view?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.